Week of May 11, 2026

This week's 13F and alternative data tracking through May 11, 2026 reveals continued concentration among specialist biotech funds in a handful of high-conviction names, with convergence signals particularly pronounced in the ion channel and oncology spaces. Xenon Pharmaceuticals (XENE) leads all tracked names in fund breadth, with 11 distinct specialist funds holding a combined $662.1 million in the stock — a level of institutional overlap that historically precedes either a significant re-rating event or heightened volatility around binary catalysts. Close behind, Revolution Medicines (RVMD) and Structure Therapeutics (GPCR) each appear in nine fund portfolios, with aggregate positions of $1.5 billion and $1.4 billion respectively, underscoring sustained institutional appetite for RAS-pathway oncology and oral GLP-1 receptor agonist plays. Edgewise Therapeutics (EWTX) and Centessa Pharmaceuticals (CNTA) round out the top convergence names with eight funds each, suggesting specialist managers are comfortable building exposure ahead of anticipated clinical and regulatory milestones in cardiac and rare disease indications.

The near-term catalyst calendar is dense, and positioning data suggests funds are actively managing risk around several imminent readouts. The most immediate event is Sinovac Biotech's (SVA) Phase 3 readout for its PCV13 pneumococcal conjugate vaccine candidate, expected May 12, followed closely by dual Phase 2 data drops on May 15 from Regeneron Pharmaceuticals (REGN) in a dupilumab expansion indication and Summit Therapeutics (SMMT) for AK112, its PD-1/VEGF bispecific antibody. The SMMT readout in particular has drawn attention given the competitive dynamics in the non-small cell lung cancer bispecific space, and any differentiation signal relative to existing PD-L1 benchmarks could catalyze meaningful position adjustments among oncology-focused funds. Later in the month, Design Therapeutics (DSGN) faces a pivotal Phase 3 data event for its abiraterone formulation program on May 18, while United Therapeutics (UTHR) closes out the month with a May 29 Phase 2 readout for rF1V-1018, a program drawing interest from funds with pulmonary and rare disease mandates.

Insider activity this week provided additional directional signals worth noting. Purchase activity at several names aligns with the convergence data, reinforcing the thesis that informed capital — both institutional and insider — is accumulating ahead of binary events rather than trimming into strength. This pattern of insider buying concurrent with multi-